Goldman Sachs’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-943,716
| Closed | -$87.7M | – | 7139 |
|
|
2021
Q4 | $87.7M | Sell |
943,716
-481,494
| -34% | -$31.7M | 0.02% | 890 |
|
|
2021
Q3 | $84.9M | Buy |
1,425,210
+493,034
| +53% | +$29.1M | 0.02% | 858 |
|
|
2021
Q2 | $63.6M | Sell |
932,176
-146,870
| -14% | -$9.57M | 0.01% | 1065 |
|
|
2021
Q1 | $74.9M | Sell |
1,079,046
-232,438
| -18% | -$17.9M | 0.02% | 854 |
|
|
2020
Q4 | $101M | Buy |
1,311,484
+418,847
| +47% | +$31.4M | 0.03% | 615 |
|
|
2020
Q3 | $66.8M | Sell |
892,637
-112,632
| -11% | -$7.51M | 0.02% | 799 |
|
|
2020
Q2 | $63.3M | Buy |
1,005,269
+514,088
| +105% | +$28.3M | 0.02% | 790 |
|
|
2020
Q1 | $20.6M | Buy |
491,181
+75,970
| +18% | +$3.48M | 0.01% | 1480 |
|
|
2019
Q4 | $18.9M | Buy |
415,211
+10,571
| +3% | +$500K | ﹤0.01% | 1925 |
|
|
2019
Q3 | $18.5M | Sell |
404,640
-53,978
| -12% | -$3.03M | 0.01% | 1842 |
|
|
2019
Q2 | $26.9M | Buy |
458,618
+71,308
| +18% | +$3.69M | 0.01% | 1617 |
|
|
2019
Q1 | $17.4M | Sell |
387,310
-85,273
| -18% | -$3.91M | 0.01% | 1995 |
|
|
2018
Q4 | $18.4M | Buy |
472,583
+128,484
| +37% | +$5.04M | 0.01% | 1864 |
|
|
2018
Q3 | $15.8M | Sell |
344,099
-126,242
| -27% | -$5.12M | ﹤0.01% | 2096 |
|
|
2018
Q2 | $20.5M | Buy |
470,341
+193,614
| +70% | +$8.32M | 0.01% | 1862 |
|
|
2018
Q1 | $10.9M | Buy |
276,727
+19,303
| +7% | +$751K | ﹤0.01% | 2256 |
|
|
2017
Q4 | $8.74M | Buy |
257,424
+77,801
| +43% | +$2.22M | ﹤0.01% | 2557 |
|
|
2017
Q3 | $4.58M | Buy |
179,623
+60,858
| +51% | +$1.4M | ﹤0.01% | 3235 |
|
|
2017
Q2 | $2M | Buy |
118,765
+63,461
| +115% | +$870K | ﹤0.01% | 3841 |
|
|
2017
Q1 | $807K | Buy |
55,304
+626
| +1% | +$9.27K | ﹤0.01% | 4578 |
|
|
2016
Q4 | $776K | Buy |
54,678
+18,561
| +51% | +$287K | ﹤0.01% | 4674 |
|
|
2016
Q3 | $632K | Sell |
36,117
-2,586
| -7% | -$42.9K | ﹤0.01% | 4815 |
|
|
2016
Q2 | $662K | Buy |
38,703
+11,219
| +41% | +$201K | ﹤0.01% | 4590 |
|
|
2016
Q1 | $541K | Sell |
27,484
-466
| -2% | -$7.47K | ﹤0.01% | 4673 |
|
|
2015
Q4 | $531K | Sell |
27,950
-18,134
| -39% | -$370K | ﹤0.01% | 4871 |
|
|
2015
Q3 | $880K | Buy |
46,084
+12,259
| +36% | +$416K | ﹤0.01% | 4599 |
|
|
2015
Q2 | $1.57M | Buy |
33,825
+8,759
| +35% | +$380K | ﹤0.01% | 4090 |
|
|
2015
Q1 | $1.1M | Buy |
25,066
+5,610
| +29% | +$261K | ﹤0.01% | 4371 |
|
|
2014
Q4 | $675K | Buy |
19,456
+396
| +2% | +$16.1K | ﹤0.01% | 4981 |
|
|
2014
Q3 | $799K | Sell |
19,060
-61,916
| -76% | -$2.76M | ﹤0.01% | 4829 |
|
|
2014
Q2 | $4.75M | Sell |
80,976
-58,520
| -42% | -$3.68M | ﹤0.01% | 3105 |
|
|
2014
Q1 | $8.79M | Buy |
139,496
+89,446
| +179% | +$5.93M | ﹤0.01% | 2486 |
|
|
2013
Q4 | $2.93M | Buy |
50,050
+518
| +1% | +$27.1K | ﹤0.01% | 3658 |
|
|
2013
Q3 | $2.61M | Sell |
49,532
-22,778
| -32% | -$1.53M | ﹤0.01% | 3661 |
|
|
2013
Q2 | $5.57M | Buy |
+72,310
| New | +$5.9M | ﹤0.01% | 2619 |
|
Goldman Sachs's ARNA Position: Q1 2022 in Review
Goldman Sachs sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 943,716 shares — an estimated $87.7M sold.
Goldman Sachs first reported a position in ARNA in Q2 2013 and held it in 35 quarters. The position peaked at $101M in Q4 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Goldman Sachs reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Goldman Sachs sold 943,716 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $87.7M.
- Goldman Sachs first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 35 quarters.
- Goldman Sachs's Arena Pharmaceuticals Inc position peaked at $101M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.